Usefulness of procalcitonin clearance as a prognostic biomarker in septic shock. A prospective pilot study

Medicina Intensiva

Volumn 36, Issue 7, 2012, Pages 475-480

  Ruiz Rodriguez J C ^a   Caballero, J ^a   Ruiz Sanmartin, A ^a   Ribas, V J ^b   Perez M ^a   Boveda J L ^a   Rello, J ^a  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^b UNIVERSITAT POLITÈCNICA DE CATALUNYA   (Spain)

Author keywords

Biomarker; Multiple organ dysfunction syndrome; Procalcitonin; Prognosis; Severe sepsis

Indexed keywords

PROCALCITONIN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; DEMOGRAPHY; FEMALE; HORMONE BLOOD LEVEL; HORMONE METABOLISM; HOSPITAL ADMISSION; HUMAN; INFECTION; INTENSIVE CARE UNIT; MALE; MORTALITY; MULTIPLE ORGAN FAILURE; OBSERVATIONAL STUDY; PILOT STUDY; PROCALCITONIN CLEARANCE; PROGNOSIS; PROSPECTIVE STUDY; SCORING SYSTEM; SEPTIC SHOCK; SURVIVAL TIME;

AGED; BIOLOGICAL MARKERS; CALCITONIN; FEMALE; HUMANS; MALE; MULTIPLE ORGAN FAILURE; PILOT PROJECTS; PROGNOSIS; PROSPECTIVE STUDIES; PROTEIN PRECURSORS; SHOCK, SEPTIC;

EID: 84865993732     PISSN: 02105691     EISSN: 15786749     Source Type: Journal    
DOI: 10.1016/j.medin.2011.11.024     Document Type: Article

References (31)

1. Becker K.L., Snider R., Nylen E.S. Procalcitonin assay in systemic inflammation, infection and sepsis: clinical utility and limitations. Crit Care Med 2008, 36:941-952.
2. Harbarth S., Holechova K., Froidevaux C., Pittet D., Ricou B., Grau G.E., et al. Diagnostic value of procalcitonin, interleukin-6, and interleukin-8 in critically ill patients admitted with suspected sepsis. Am J Respir Crit Care Med 2001, 64:396-402.
3. Simon L., Gauvin F., Amre D.K., Saint-Louis P., Lacroix J. Serum procalcitonin and C-reactive protein levels as markers of bacterial infection: a systematic review and meta-analysis. Clin Infect Dis 2004, 39:206-217.
4. Jensen J.U., Heslet L., Ensen T.H., Espersen K., Steffensen P., Tvede M.K. Procalcitonin increase in early identification of critically ill patients with a high risk of mortality. Crit Care Med 2006, 34:2596-2606.
5. Clec'h C., Ferriere F., Karoubi P., Fosse J., Cupa M., Hoang P., et al. Diagnostic and prognostic value of procalcitonin in patients with septic shock. Crit Care Med 2004, 32:1166-1199.
6. Seligman R., Meisner M., Lisboa T.C., Hertz F.T., Filippin T.B., Fachel J.M.G., et al. Decreases in procalcitonin and C-reactive protein are strong predictors in ventilator-associated pneumonia. Crit Care 2006, 10:R 125.
7. Boussekey N., Leroy O., Alfandari S., Devos P., Georges H., Guery B. Procalcitonin kinetics in the prognosis of severe community-acquired pneumonia. Intensive Care Med 2006, 32:469-472.
8. Müller B., Harbarth S., Stolz D., Bingisser R., Mueller C., Leuppi J., et al. Diagnostic and prognostic accuracy of clinical and laboratory parameters in community-acquired pneumonia. BMC Infect Dis 2007, 7:10.
9. Menendez R., Cavalcanti M., Reyes S., Mensa J., Martinez R., Marcos M.A., et al. Markers of treatment failure in hospitalised community acquired pneumonia. Thorax 2008, 693:447-452.
10. Ramirez P., García M.A., Ferrer M., Aznar J., Valencia M., Sahuquillo J.M., et al. Sequential measurements of procalcitonin levels in diagnosis ventilator-associated pneumonia. Eur J Respir 2008, 31:356-362.
11. Menendez R., Martinez R., Reyes S., Mensa J., Polverino E., Filella X., et al. Stability in community-acquired pneumonia: one step forward with markers?. Thorax 2009, 64:987-992.
12. Müller F., Christ-Crain M., Bregenzer T., Krause M., Zimmerli W., Mueller B., et al. Procalcitonin levels predict bacteraemia in patients with community-acquired pneumonia. A prospective cohort trial. Chest 2010, 138:121-215.
13. Claessens Y.E., Mathevon T., Kierzek G., Grabar S., Jegou D., Batard E., et al. Accuracy of C-reactive protein, procalcitonin and mid-regional pro-atrial natriuretic peptide to guide site of care of community-acquired pneumonia. Intensive Care Med 2010, 36:799-809.
14. Nobre V., Harbarth S., Graf J.D., Rohner P., Pugin J. Use of procalcitonin to shorten antibiotic treatment duration of septic patients. Am J Respir Crit Care Med 2008, 177:498-505.
15. Bouadma L., Luyt C.E., Tubach F., Cracco C., Alvarez A., Schwebel C., et al. Use of procalcitonin to reduce patient's exposure to antibiotics in intensive care units (PRORATA trial): a multicentre randomised controlled trial. Lancet 2010, 375:463-474.
16. Kopterides P., Siempos I.I., Tsangaris I., Tsantes A., Armaganidis A. Procalcitonin-guided algorithms of antibiotic therapy in the intensive care unit: a systematic review and meta-analysis of randomized controlled trials. Crit Care Med 2010, 38:2229-2241.
17. Levy M.M., Fink M.P., Marshall J.C., Abraham E., Angus D., Cook D., et al. 2001 SCCM/ESICM/ACCP/ATS/SIS international sepsis definitions conference. Intensive Care Med 2003, 29:530-538.
18. Dellinger R.P., Levy M.M., Carlet J.M., Julian Bion J., Parker M.M., Jaeschke R., et al. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2008. Intensive Care Med 2008, 34:17-60.
19. Hollenberg S.M., Ahrens T.S., Annane D., Astiz M.E., Chalfin D.B., Dasta J.F., et al. Practice parameters for hemodynamic support of sepsis in adult patients: 2004 update. Crit Care Med 2004, 32:1928-1948.
20. Vincent J.L., Moreno R., Takala J., Wilatts S., de Mendonça A., Bruining H., et al. The SOFA (sepsis-related organ failure assessment) score to describe organ dysfunction/failure. On behalf of the working group on Sepsis-Related Problems of the European Society of Intensive Care Medicine. Intensive Care Med 1996, 22:707-710.
21. Clec'h C., Fosse J.P., Karoubi P., Vincent F., Chouachi I., Hamza L., et al. Differential diagnostic value of procalcitonin in surgical and medical patients with septic shock. Crit Care Med 2008, 34:102-107.
22. Claeys R., Vinken S., Spapen H., ver Elst K., Decochez K., Huyghens L., et al. Plasma procalcitonin and C-reactive protein in acute septic shock: clinical and biological correlates. Crit Care Med 2002, 30:757-762.
23. Charles P.E., Tinel C., Barbar S., Aho S., Prin S., Doise J.M., et al. Procalcitonin kinetics within the first days of sepsis: relationship with the appropriateness of antibiotic therapy and outcome. Crit Care 2009, 13:R38.
24. Karlsson S., Heikkinen M., Pettilä V., Alila S., Väisänen S., Pulkki K., et al. Predictive value of procalcitonin decrease in patients with severe sepsis: a prospective observational study. Crit Care 2010, 14:R205.
25. Meisner M., Schmidt J., Huerrner H., Tschaikowsky K. The natural elimination rate of procalcitonin in patients with normal and impaired renal function. Intensive Care Med 1999, 26:212-216.
26. Christ-Cain M., Stolz D., Bingisser R., Müller C., Miedinger D., Huber P.R., et al. Procalcitonin guidance of antibiotic therapy in community-acquired pneumonia. Am J Respir Crit Care Med 2006, 174:84-93.
27. Muller B., Becker K., Schachinger H., Rickenbacher P.R., Huber P.R., Zimmerli W., et al. Calcitonin precursors are reliable markers of sepsis in a medical intensive care unit. Crit Care Med 2000, 28:977-983.
28. Meisner M., Adina H., Schmidt J. Correlation of procalcitonin and C-reactive protein to inflammation, complications and outcome during the intensive care course of multiple-trauma patients. Crit Care 2006, 10:R1.
29. Van der Kaay D.C.M., De Kleijn E.D., De Ridjke Y.B., Hop W.C.J., De Groot R., Hazelzet J.A. Procalcitonin as a prognostic marker in meningococcal disease. Intensive Care Med 2002, 28:1606-1612.
30. Meisner M., Tschaikowsky K., Palmaers T., Schmidt J. Comparison of procalcitonin (PCT) and C-reactive protein (CRP) plasma concentrations at different SOFA scores during the course of sepsis and MODS. Crit Care 1999, 3:45-50.
31. Hochreiter M., Köhler T., Schweiger A.M., Keck F.S., Bein B., von Spiegel T., et al. Procalcitonin to guide duration of antibiotic therapy in intensive care patients: a randomized prospective controlled trial. Crit Care 2009, 13:R83.